Edition:
United Kingdom

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

105.55USD
17 Aug 2018
Change (% chg)

$1.19 (+1.14%)
Prev Close
$104.36
Open
$104.43
Day's High
$105.92
Day's Low
$104.30
Volume
965,619
Avg. Vol
983,582
52-wk High
$105.92
52-wk Low
$73.70

Select another date:

Tue, Jul 24 2018

Deals of the day-Mergers and acquisitions

July 24 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Tuesday:

Lilly plans Elanco IPO, posts quarterly profit above estimates

Eli Lilly and Co said on Tuesday it would take its Elanco animal health business public and posted a better-than-expected quarterly profit, helped by demand for its diabetes drugs Trulicity and Humalog.

Eli Lilly posts quarterly loss

July 24 Eli Lilly and Co posted a second-quarter loss on Tuesday, hurt by acquisition-related charges to the tune of $1.62 billion.

Pfizer-Lilly pain drug meets late-stage trial goals

An experimental osteoarthritis drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of lowering pain in a late stage trial, the companies said on Wednesday, potentially offering a safer alternative to opioids.

Pfizer-Lilly pain drug found effective in late-stage study

July 18 An experimental drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of reducing pain in osteoarthritis patients in a late stage trial, the companies said on Wednesday.

Novo reveals more Ozempic data on change in body weight by baseline BMI

COPENHAGEN, June 23 Diabetes drugmaker Novo Nordisk presented a post-hoc analysis of the SUSTAIN 7 trial comparing treatment effect in body weight across baseline BMI subgroups receiving Novo's Ozempic or Eli Lilly's dulaglutide, marketed as Trulicity.

UPDATE 2-Lilly gets U.S. nod for arthritis drug, sets price well below rivals

* Drug priced at $25,000/year, 60 pct lower to AbbVie's Humira

Novo Nordisk's oral diabetes drug beats Jardiance in study

LONDON, May 29 An experimental diabetes pill from Novo Nordisk proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim's established Jardiance in a clinical study, the Danish drugmaker said on Tuesday.

Lilly to buy cancer drug developer AurKa Pharma

Eli Lilly and Co will buy AurKa Pharma Inc in a deal potentially worth up to $575 million, the U.S. drugmaker said on Monday, seeking access to the privately-held firm's experimental cancer treatment for solid tumors.

Eli Lilly to buy cancer drug developer AurKa Pharma

May 14 Drugmaker Eli Lilly and Co said on Monday it would buy AurKa Pharma Inc to get access to the privately-held company's experimental cancer treatment for solid tumors.

Select another date: